After disappointing Wall Street last year, Denali touts new biomarker data hoping to forge clear path to FDA

Max Gelman

Senior Editor

Looking to build out a case for its drugs that can better penetrate the blood-brain barrier, Denali Therapeutics touted new interim Hunter syndrome data Wednesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After disappointing Wall Street last year, Denali touts new biomarker data hoping to forge clear path to FDA

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Sanofi introduces new 340B payment model — report

Af­ter dis­ap­point­ing Wall Street last year, De­nali touts new bio­mark­er da­ta hop­ing to forge clear path to FDA

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

After disappointing Wall Street last year, Denali touts new biomarker data hoping to forge clear path to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Sanofi introduces new 340B payment model — report